Which has higher valuation and earnings, BRNS or NRSN?

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$10.80 N/A

Is BRNS or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% NeuroSense Therapeutics N/A N/A N/A

Is NRSN or MDXH more profitable?

NeuroSense Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A MDxHealth -33.46% N/A -24.25%

Does the media refer more to NRSN or MDXH?

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 3 articles in the media. NeuroSense Therapeutics' average media sentiment score of 0.32 beat MDxHealth's score of -0.09 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, CNTX or NRSN?

Context Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$10.80 N/A

Is CNTX or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% NeuroSense Therapeutics N/A N/A N/A

Do analysts prefer RNAZ or NRSN?

NeuroSense Therapeutics has a consensus price target of $170.00, suggesting a potential upside of 4,350.26%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, RNAZ or NRSN?

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$10.80 N/A

Is RNAZ or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% NeuroSense Therapeutics N/A N/A N/A

Does the media refer more to RNAZ or NRSN?

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.44 beat NeuroSense Therapeutics' score of 0.32 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroSense Therapeutics (NRSN) Competitors

$3.82 0.00 (0.00%)

As of 11:19 AM Eastern

Compare

NRSN vs. BRNS, MDXH, CNTX, RNAZ, and MCRB

Should you buy NeuroSense Therapeutics stock or one of its competitors? NeuroSense Therapeutics's main competitors and comparable companies include Barinthus Biotherapeutics (BRNS), MDxHealth (MDXH), Context Therapeutics (CNTX), TransCode Therapeutics (RNAZ), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NeuroSense Therapeutics compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
NeuroSense Therapeutics	N/A	N/A	N/A

Barinthus Biotherapeutics has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A

In the previous week, NeuroSense Therapeutics had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 0 mentions for Barinthus Biotherapeutics. NeuroSense Therapeutics' average media sentiment score of 0.32 beat Barinthus Biotherapeutics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
NeuroSense Therapeutics	Neutral

Barinthus Biotherapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 440.47%. NeuroSense Therapeutics has a consensus price target of $170.00, suggesting a potential upside of 4,350.26%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

NeuroSense Therapeutics beats Barinthus Biotherapeutics on 12 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to MDxHealth?

NeuroSense Therapeutics (NASDAQ:NRSN) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

NeuroSense Therapeutics has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A
MDxHealth	$107.88M	0.28	-$33.52M	-$0.72	N/A

NeuroSense Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
MDxHealth	-33.46%	N/A	-24.25%

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 3 articles in the media. NeuroSense Therapeutics' average media sentiment score of 0.32 beat MDxHealth's score of -0.09 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroSense Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

NeuroSense Therapeutics currently has a consensus target price of $170.00, suggesting a potential upside of 4,350.26%. MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 261.23%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroSense Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

NeuroSense Therapeutics beats MDxHealth on 10 of the 13 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NeuroSense Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
NeuroSense Therapeutics	N/A	N/A	N/A

Context Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,872.70%. NeuroSense Therapeutics has a consensus target price of $170.00, suggesting a potential upside of 4,350.26%. Given NeuroSense Therapeutics' higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Context Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

In the previous week, NeuroSense Therapeutics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 0 mentions for Context Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.32 beat Context Therapeutics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Context Therapeutics	Neutral
NeuroSense Therapeutics	Neutral

Summary

NeuroSense Therapeutics beats Context Therapeutics on 9 of the 13 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

NeuroSense Therapeutics has a consensus price target of $170.00, suggesting a potential upside of 4,350.26%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A

NeuroSense Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
NeuroSense Therapeutics	N/A	N/A	N/A

TransCode Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.44 beat NeuroSense Therapeutics' score of 0.32 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroSense Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeuroSense Therapeutics beats TransCode Therapeutics on 12 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Seres Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NeuroSense Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Seres Therapeutics has higher revenue and earnings than NeuroSense Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A
Seres Therapeutics	$790K	34.60	$5.70M	-$2.43	N/A

In the previous week, NeuroSense Therapeutics had 4 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.75 beat NeuroSense Therapeutics' score of 0.32 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroSense Therapeutics	Neutral
Seres Therapeutics	Positive

NeuroSense Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. NeuroSense Therapeutics' return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

NeuroSense Therapeutics presently has a consensus price target of $170.00, suggesting a potential upside of 4,350.26%. Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 525.00%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

NeuroSense Therapeutics beats Seres Therapeutics on 11 of the 16 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.26M	$3.81B	$7.12B	$13.32B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-0.35	13.71	275.34	26.03
Price / Sales	N/A	1,189.72	575.56	85.81
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	-3.98	16.06	10.76	6.24
Net Income	-$11.12M	-$22.65M	$3.50B	$381.89M
7 Day Performance	-5.68%	-3.67%	-1.99%	-1.29%
1 Month Performance	-54.32%	-12.91%	-7.52%	-5.52%
1 Year Performance	-84.34%	8.61%	2.87%	-1.47%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	2.8352 of 5 stars	$3.82 flat	$170.00 +4,350.3%	-83.4%	$7.26M	N/A	N/A	16
BRNS Barinthus Biotherapeutics	1.7526 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
MDXH MDxHealth	2.2521 of 5 stars	$0.60 +0.5%	$2.17 +261.1%	-87.4%	$29.70M	$107.88M	N/A	364	News Coverage
CNTX Context Therapeutics	2.0681 of 5 stars	$0.33 -3.1%	$6.17 +1,791.6%	-72.3%	$29.49M	N/A	N/A	15
RNAZ TransCode Therapeutics	0.3855 of 5 stars	$1.72 -2.1%	N/A	-85.3%	$28.88M	N/A	N/A	12	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. BRNS, MDXH, CNTX, RNAZ, and MCRB

How does NeuroSense Therapeutics compare to Barinthus Biotherapeutics?

Summary

How does NeuroSense Therapeutics compare to MDxHealth?

Summary

How does NeuroSense Therapeutics compare to Context Therapeutics?

Summary

How does NeuroSense Therapeutics compare to TransCode Therapeutics?

Summary

How does NeuroSense Therapeutics compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. BRNS, MDXH, CNTX, RNAZ, and MCRB

How does NeuroSense Therapeutics compare to Barinthus Biotherapeutics?

Do insiders and institutionals hold more shares of BRNS or NRSN?

Is BRNS or NRSN more profitable?

Which has more volatility & risk, BRNS or NRSN?

Which has higher valuation and earnings, BRNS or NRSN?

Does the media refer more to BRNS or NRSN?

Do analysts prefer BRNS or NRSN?

Summary

How does NeuroSense Therapeutics compare to MDxHealth?

Which has preferable earnings and valuation, NRSN or MDXH?

Is NRSN or MDXH more profitable?

Do insiders & institutionals have more ownership in NRSN or MDXH?

Does the media refer more to NRSN or MDXH?

Which has more risk & volatility, NRSN or MDXH?

Do analysts recommend NRSN or MDXH?

Summary

How does NeuroSense Therapeutics compare to Context Therapeutics?

Do institutionals & insiders hold more shares of CNTX or NRSN?

Is CNTX or NRSN more profitable?

Which has higher earnings and valuation, CNTX or NRSN?

Do analysts rate CNTX or NRSN?

Which has more volatility & risk, CNTX or NRSN?

Does the media prefer CNTX or NRSN?

Summary

How does NeuroSense Therapeutics compare to TransCode Therapeutics?

Do analysts prefer RNAZ or NRSN?

Which has higher valuation & earnings, RNAZ or NRSN?

Is RNAZ or NRSN more profitable?

Which has more risk & volatility, RNAZ or NRSN?

Do institutionals and insiders have more ownership in RNAZ or NRSN?

Does the media refer more to RNAZ or NRSN?

Summary

How does NeuroSense Therapeutics compare to Seres Therapeutics?

Do insiders and institutionals hold more shares of NRSN or MCRB?

Which has more risk and volatility, NRSN or MCRB?

Which has higher valuation and earnings, NRSN or MCRB?

Does the media prefer NRSN or MCRB?

Is NRSN or MCRB more profitable?

Do analysts rate NRSN or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools